Dynamic quotes: Off
|
ETFs with NEO as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 3.77% | iShares Dow Jones EPAC Select Dividend (IDV) | +2.32 (6.97%) |
| 3.23% | Guggenheim Global Dividend Opportunities Index ETF (LVL) | +0.92 (7.43%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
NeoGenomics, Inc., a Nevada corporation (referred to individually as the “Parent Company” or collectively with its subsidiaries as “NeoGenomics”, “we”, “us”, “our” or the “Company” in this Form 10-K) is the registrant for SEC reporting purposes. Our common stock is listed on the NASDAQ Capital Market under the symbol “NEO”. Overview We operate a network of cancer-focused testing laboratories whose mission is to improve patient care through exceptional genetic and molecular testing services. Our vision is to become America’s premier cancer testing laboratory by delivering uncompromising quality, exceptional service and innovative products and services. The Company has laboratory locations in Ft. Myers and Tampa, Florida; Irvine, California; and Nashville, Tennessee, and currently offers the following types of testing services: a) Cytogenetics testing – the study of normal and abnormal chromosomes and their relationship to disease. ... More ...
Analyst Info |
|
| Annual EPS Est: | $0 |
| Quarterly EPS Est: | 0.01 |
| PEG Ratio: | 4.43 |
|
Mean Recommendation: View Summary / View All |
1.5 |
Data is provided by Zacks Investment Research

